MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation

Trial Profile

MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Ixazomib (Primary)
  • Indications Graft-versus-host disease; Haematological malignancies
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Sep 2015 Planned number of patients changed from 63 to 57 as reported by ClinicalTrials.gov
    • 20 Nov 2014 Status changed from not yet recruiting to recruiting as per ClinicalTrial.gov record.
    • 30 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top